Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* NIVEN RALPH						2. Issuer Name and Ticker or Trading Symbol Aerovate Therapeutics, Inc. [AVTE]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify						
	ROVATE T	irst) HERAPEUTICS EET, SUITE M-5	-		11/	3. Date of Earliest Transaction (Month/Day/Year) 11/07/2022								A below	below) below) CHIEF SCIENTIFIC OFFICER					
(Street) WALTH	reet) ALTHAM MA 02451			- 4. 1 -	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City)	ity) (State) (Zip)																			
		Tab	le I - N	on-Deri	vative	Sec	uriti	es Ac	· ·	 -				lly Owne	ed .					
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed Of Code (Instr.		es Acquired (A) or Of (D) (Instr. 3, 4 and 5)		5) Securi Benefi Owned	5. Amount of Securities Beneficially Owned Following Reported		Direct of the di	7. Nature of Indirect Beneficial Ownership (Instr. 4)						
								Code V	Amo	unt	(A) or (D)	Price	Transa	Transaction(s) (Instr. 3 and 4)						
Common	mon Stock 11/07		11/07/	2022	022		M ⁽¹⁾	(50	A	\$1.74	4 2	2,259							
Common	Common Stock 11/0		11/07/	2022	022		M ⁽¹⁾	1,	600	A	\$2.14	4 3	3,859							
Common Stock		11/07/	2022	022			S ⁽¹⁾		50	D	\$17.09	1 ⁽²⁾	3,409							
Common	Common Stock 11/0		11/07/	2022	022		S ⁽¹⁾	1	55	D	\$18.02	3 ⁽³⁾	3,254							
Common Stock 11/07			11/07/	2022)22			S ⁽¹⁾	1,	430	D	\$19.82	3 ⁽⁴⁾	1,824						
Common Stock 11/07/2			2022)22		S ⁽¹⁾	2	15	D	\$20.29	3 ⁽⁵⁾ 1	1,609								
		Т	able II											y Owned						
Derivative Conversion Date Executive Or Exercise (Month/Day/Year)		if any			action	5. Number of		6, Options, converti 6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		ly O). wnership orm: irect (D) r Indirect (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
					Code	v	(A)	(D)	Date Exercisabl	Expir e Date	ation	Title	Amount or Number of Shares	1						
Stock Option (Right to Buy)	\$1.74	11/07/2022			M ⁽¹⁾			450	(6)	09/03	2030	Common Stock	450	\$0	22,308	3	D			
Stock																				
Option (Right to Buy)	\$1.74	11/07/2022			M ⁽¹⁾			200	(7)	09/03	2030	Common Stock	200	\$0	13,688	3	D			
(Right to	\$1.74 \$2.14	11/07/2022			M ⁽¹⁾			200	(7)	09/03			200	\$0 \$0	13,688	+	D D			
(Right to Buy) Stock Option (Right to										+	2031	Stock				1				

Explanation of Responses:

Buy)

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$16.67 to \$17.41, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

- 3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$17.70 to \$18.62, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- 4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$19.15 to \$20.14, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- 5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$20.21 to \$20.51, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- 6. A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter
- 7. A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly

installments thereafter.

8. A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021.

9. A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021.

10. A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021.

/s/ George A. Eldridge, Attorney-in-Fact

11/09/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.